Stay updated with breaking news from Graphite Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Graphite Bio (NASDAQ:GRPH – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, “Graphite Bio Inc. is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc. is […]
A bullish trade idea from Real Money's Bret Jensen on the XBI biotech ETF using covered calls...XBI
Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) has been assigned an average recommendation of “Hold” from the seven analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The […]
Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease - read this article along with other careers information, tips and advice on BioSpace
Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) saw a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 2,580,000 shares, a decline of 36.0% from the March 31st total of 4,030,000 shares. Approximately 10.7% of the company’s shares are sold short. Based on an average […]